

# Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

S. Vincent Rajkumar,  
Laura Rosiñol,  
Mohamad Hussein,  
John Catalano,  
Wieslaw Jedrzejczak,  
Lela Lucy,  
Marta Olesnyckyj,  
Zhinuan Yu,  
Robert Knight,  
Jerome B. Zeldis and  
Joan Bladé

## Appendix

The following are MM003 investigators and participating institutions.

### North America

#### Canada.

M. Voralia (Saskatoon Cancer Center, Saskatoon Saskatchewan), D. White (Queen Elizabeth II Health Services Centre, Halifax).

#### United States.

J. Berenson (Berenson Oncology, West Hollywood), L. Bertoli (Clinical Research Consultants Inc, Hoover), T. Dobbs (Baptist Regional Cancer Center, Knoxville), H. Fernandez (Miami), M. Goodman (University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami), D. Gravenor (The Family Cancer Center, Collierville), S. Gregory (Rush University Medical Center, Chicago), J. Hays, Centralia, D. Hurd (Wake Forest University School of Medicine, Winston-Salem), M. Hussein (Cleveland), A. Jakubowiak (University of Michigan, Ann Arbor), R. Lambert-Falls (South Carolina Oncology Assoc, Columbia), M. Modiano (Arizona Clinical Research Center, Tucson), S.V. Rajkumar (Mayo Clinic Cancer Center, Rochester), G.D. Roodman (University of Pittsburgh, VA Pittsburgh Health Care System, Pittsburgh), V. Roy (Mayo Clinic, Jacksonville), G. Schiller (University of California, Los Angeles School of Medicine, Los Angeles), R. Sobecks (Cleveland Clinic, Cleveland), D. Vesole, Milwaukee, J. Wade (Medical College of Wisconsin, Milwaukee).

### Europe

#### Belgium.

D. Bron (Institut Bordet, Brussel), L. Noens (Gent) A. Janssens (UZ Gent, Gent), H. Schots (VUB, Brussel).

#### Bulgaria.

D. Peytchev (National Center of Hematology and Transfusiology, Sofia).

#### Hungary.

Z. Gasztanyi (Petz Aladar Country Hospital, Gyor).

#### Italy.

M. Baccarani (Policlinico Sant'Orsola-Malpighi, Bologna), F. Dammacco (Universita di Bari Dipartimento di Scienze Biomediche, Bari); R. Fanin (Policlinico Universitario a Gestione diretta di Udine, Udine), R. Foa (Univerita La Sapien, Roma),

M. Gobbi (Azienda Ospedaliera San Martino, Genova), M. Lazzarino (Policlinico San Matteo/Viale C. Golgi, Pavia), E. Morra (Ospedale Niguarda Ca Granda, Milano).

### **Poland.**

A. Dmoszynska (University School of Medicine, Lublin), A. Hellmann (Institute of Internal Diseases, University of Medicine, Gdansk), W. Jedrzejczak (Akademia Medyczna w Warszawie Samodzielny Publiczny Centralny Szpital Kliniczny, Warsaw), J. Kloczko (Klinika Hematologii Samodzielny Publiczny Szpital Kliniczny Akademii, Bialystok), A. Pluzanska (Uniwersytet Medyczny w Lodzi, Lodz), A. Skotnicki (Oddzial Kliniczny Kliniki Hematologii, Krakow).

### **Spain.**

A. Alegre (Hospital Universitario de la Princesa, Madrid), J. Baro (Hospital Universitario Marques de Valdecilla, Santander), J. Blade (Hospital Clinic, Barcelona), J.-J. Lahuerta (Hospital Doce de Octubre, Madrid), F. Prosper (Clinica Universitaria de Navarra, Pamplona), J. San Miguel (Hospital Universitario de Salamanca, Salamanca).

### **United Kingdom.**

M. Drake (Belfast City Hospital Hematology Department, Belfast), Kazmi, London, S. Steve (Kings College Hospital, London).

### **International**

#### **Australia.**

J. Catalano (Frankston Hospital Oncology Research, Frankston), D. Gill (Princess Alexandra Hospital, Woolloongabba), M. Prince (Peter MacCallum Cancer Centre Division of Hematology/Medical Oncology, East Melbourne), A. Spencer (The Alfred Hospital, Melbourne), J. Szer (The Royal Melbourne Hospital, Melbourne), P. Wood (Royal Brisbane Hospital, Herston).

#### **Israel.**

B. Yehuda (Hadassah University Hospital, Jerusalem), A. Nagler (The Chaim Sheba Medical Center, Tel Hashomer), E. Naparstek (Tel Aviv Sourasky Medical Center Department of Hematology, Tel Aviv), J. M Rowe (Rambam Medical Center, Haifa).

#### **Russia.**

K. Abdulkadyrov (Institute of Hematology and Blood Transfusion St Petersburg Research, St Petersburg), B. Afanasjev (St Petersburg Pavlov State Medical University Hematology Center, St Petersburg), N. Domnikova, (Novosibirsk State Regional Clinical Hospital, Novosibirsk), T. Konstantinova (Ekaterinburg first Regional Hospital, Ekaterinburg), A. Korobkin (Chelyabinsk Regional Clinical Hospital, Medgarodok Chelyabinski), T. Lysaya (Zhitomir Regional Clinical Hospital, Zhitomir), D. Osmanov (Blokhin Cancer Research Center, Moscow), E. Podoltseva (St Petersburg Hospital #31, St Petersburg), V. Rossiev (Samara Regional Clinical Hospital, Samara), O. Rukavitsin (Burdenko Central Military Clinical Hospital, Moscow), O. Samoiloa (Nizhny Novgorod Clinical Hospital, Nizhny Novgorod), V. Savchenko (Russian Academy of Medical Sciences, Moscow), A. Suvorov (Republican Clinical Hospital #1, Izhevsk).

#### **Ukraine.**

G. Babak (Zaporozhje Regional Clinical Hospital, Zaporozhje), A. Dudnichenko (Kharkov Regional Clinical Oncology Center, Kharkov); N. Glushko (Ivano-Frankovsk Regional Clinical Hospital, Ivano-Frankovsk), P. Kaplan (Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk), E. Karamanesht (Kiev Bone Marrow Transplantation Center, Bone Marrow Department, Kiev), V. Kozlov (Odessa Regional Clinical Hospital, Odessa), Z. Masliak, (Institute of Blood Pathology and Transfusion Medicine of the UAMS Hematology Department, Lviv), G. Pilipenko (Cherkassy Regional Oncology Center, Cherkassy), S. Sivkovich (Kiev Institute of Oncology of the UAMS Systemic Malignancies Department, Kiev), N. Tretyak (Institute of Hematology and Transfusiology of the UAMS Department of Blood Diseases, Kiev).